In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fastenal Company (NASDAQ:FAST),...
Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019
APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation...
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR(TM)...
Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation
Achieves Record Annual IXINITY Net Revenue of $23.1 Million Representing 111% Increase Over 2017
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering...
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject...
ADAPTIR(TM) Bispecific Antibody Candidates Poised to Progress in Clinical Development
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from...
Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement
Stock Monitor: Aptevo Therapeutics Post Earnings Reporting
Almost Doubles Year-Over-Year IXINITY Quarterly Revenue
ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications
On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.
Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.
With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.